Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 9/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.81 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.81 |
| ▸ | TSHR | P16473 | 2/20 | 0.81 |
| ▸ | MEN1 | O00255 | 6/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.69 |
| ▸ | TP53 | P04637 | 4/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.69 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.65 |
| ▸ | AR | P10275 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.61 |
| ▸ | TNKS | O95271 | 2/20 | 0.61 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | PKM | P14618 | 2/20 | 0.60 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.60 |
| ▸ | MAOA | P21397 | 2/20 | 0.60 |
| ▸ | MAOB | P27338 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31675843 | 0.90 | CYP3A4 (1.00) | HPGDCYP3A4ALDH1A1CYP2C19TSHR | |
| SCHEMBL4626639 | 0.90 | CYP3A4 (1.00) | HPGDCYP3A4ALDH1A1CYP2C19TSHR | |
| 7,2'-Dimethoxyflavone SCHEMBL4285153 | 0.85 | AR (0.81) | HPGDCYP3A4ALDH1A1CYP2C19TSHR | |
| SCHEMBL253522 | 0.85 | HPGD (0.78) | HPGDCYP3A4ALDH1A1CYP2C19TSHR | |
| SCHEMBL28152050 | 0.82 | PABPC1 (0.70) | HPGDCYP3A4ALDH1A1CYP2C19TSHR | |
| SCHEMBL29373668 | 0.82 | MEN1 (1.00) | HPGDCYP3A4ALDH1A1CYP2C19TSHR | |
| SCHEMBL131759 | 0.82 | MEN1 (1.00) | HPGDCYP3A4ALDH1A1CYP2C19TSHR | |
| SCHEMBL12909284 | 0.82 | USP2 (0.67) | HPGDCYP3A4ALDH1A1CYP2C19TSHR | |
| SCHEMBL7075361 | 0.80 | AR (0.65) | HPGDCYP3A4ALDH1A1CYP2C19TSHR | |
| SCHEMBL30228520 | 0.80 | CA12 (0.65) | HPGDCYP3A4ALDH1A1CYP2C19TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6872771-B1 | Tire with rubber containing flavone | THE GOODYEAR TIRE & RUBBER COMPANY (US) | 2005-03-29 | — | — | US | claimed |
| EP-2730431-B1 | Rubber composition and tire with rubber containing flavone | GOODYEAR TIRE & RUBBER (US) | 2017-06-28 | — | — | EP | disclosed |
| US-20140135433-A1 | TIRE WITH RUBBER CONTAINING FLAVONE | THE GOODYEAR TIRE & RUBBER COMPANY (US) | 2014-05-15 | — | — | US | disclosed |
| EP-2730431-A1 | Rubber composition and tire with rubber containing flavone | The Goodyear Tire & Rubber Company (US) | 2014-05-14 | — | — | EP | disclosed |
| EP-1391327-B1 | Tire with rubber containing flavone | GOODYEAR TIRE & RUBBER (US) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007115181-A9 | COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF | EASTMAN CHEM CO (US) | 2008-04-03 | — | — | WO | disclosed |
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | EASTMAN CHEMICAL COMPANY | 2007-11-01 | — | — | US | disclosed |
| WO-2007115181-A2 | COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF | EASTMAN CHEMICAL COMPANY (US) | 2007-10-11 | — | — | WO | disclosed |
| US-6872771-B1 | Tire with rubber containing flavone | THE GOODYEAR TIRE & RUBBER COMPANY (US) | 2005-03-29 | — | — | US | disclosed |
| EP-1391327-A1 | Tire with rubber containing flavone | THE GOODYEAR TIRE & RUBBER COMPANY (US) | 2004-02-25 | — | — | EP | disclosed |
| US-6610738-B2 | Treatment of Alzheimer's Disease by combining both acetylcholinesterase inhibitory activity and antioxidant activity (by virtue of their carbamoyl and flavonoid pharmacophores) | BIOGAL PHARMACEUTICAL CO., LTD. (HU) | 2003-08-26 | — | — | US | disclosed |
| WO-2003057210-A1 | COMPOSITIONS AND METHODS FOR INCREASING CELL PROLIFERATION COMPRISING A FLAVONOID | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2003-07-17 | — | — | WO | disclosed |
| US-20030125264-A1 | Methods For Treating Wounds | KIMBERLY-CLARK WORLDWIDE, INC. | 2003-07-03 | — | — | US | disclosed |
| EP-1322632-A1 | N-DISUBSTITUTED CARBAMOYLOXY FLAVONES | Biogal Pharmaceutical Co., Ltd (HU) | 2003-07-02 | — | — | EP | disclosed |
| US-20020128494-A1 | N-Disubstituted carbamoyloxy flavones | BIOGAL PHARMACEUTICAL CO., LTD. (HU) | 2002-09-12 | — | — | US | disclosed |
| WO-2002024676-A1 | N-DISUBSTITUTED CARBAMOYLOXY FLAVONES | TEVA PHARMACEUTICALS INDUSTRIES, LTD. (IL) | 2002-03-28 | — | — | WO | disclosed |
| WO-2002024677-A1 | N-DISUBSTITUTED CARBAMOYLOXY FLAVONES | BIOGAL PHARMACEUTICAL CO., LTD. (HU) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | ABCC4, NCOA4, NR4A3 | HPGD 1949/4885CYP3A4 17/4885ALDH1A1 2000/4885 |
| US-20020128494-A1 | N-Disubstituted carbamoyloxy flavones | CBR3, FOS, CBR1 | HPGD 2446/4885CYP3A4 1040/4885ALDH1A1 3001/4885 |
| US-20030125264-A1 | Methods For Treating Wounds | FGF2, MMP1, FIBP | HPGD 558/4885CYP3A4 3010/4885ALDH1A1 2440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.